

## 2021 Independent Medical Education Call for Grant Notification

**Issue Date: May 7, 2021**

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Call for Grants Notification (CGN) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

**COVID-19 Notice:** Please consider the national as well as state safety guidelines for vaccinated and unvaccinated individuals involved with in-person gatherings at the present time due to the ongoing COVID-19 pandemic.

**Purpose:** As part of Genentech's scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

**Notification:** Genentech CGNs are made available through our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (<http://funding.gene.com>) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

### Terms and Conditions

1. All grant applications received in response to this CGN will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on <http://funding.gene.com>)
2. This CGN does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this CGN.
4. For compliance reasons, and in fairness to all providers, all communications about this CGN must come exclusively to Genentech's department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this CGN may result in a denial.

### Instructions

Eligibility Criteria	<ul style="list-style-type: none"><li>• U.S. based education provider</li><li>• Registered account in gFRS</li><li>• Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)</li></ul>
Geographical Scope	<ul style="list-style-type: none"><li>• Educational initiatives must be U.S.-based only</li></ul>

Submission Directions	Application Process	Deadlines
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this CGN will have 2.5 weeks to complete a <b>full grant proposal</b> through <a href="https://funding.gene.com">funding.gene.com</a> . When submitting the application, please be sure to: <ul style="list-style-type: none"> <li>Select the Therapeutic Area (Neuroscience), and Disease State (Multiple Sclerosis)</li> <li>Include "CGN May 2021 [Insert Program Title]" in the program title of the grant</li> </ul>	May 26, 2021
Step 2	Grant decisions will be made by Genentech within 1 week of May 26, 2021, and decision notifications will be issued to the accredited educational provider through our grant platform as per usual.	June 2, 2021
Step 3	Due to the timely nature of the education related to the COVID-19 pandemic, we ask that programs launch within 4 weeks of the decision date.	June 30, 2021

#### Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or improved patient outcomes as a result of the educational activity.
3. Summarize (through written analysis) the provider's understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

#### Currently Available CGN Focus Area:

Focus	Opportunity
<b>Therapeutic Area:</b> Neuroscience  <b>Disease Areas:</b> Multiple Sclerosis  <b>Learning Audience:</b> General/Community Neurologists  Entire care team that supports MS patients (example: MS specialists, PAs, NPs, nurses, pharmacists)  Patients	<p>The COVID-19 pandemic has changed the way multiple sclerosis care is delivered in the US. As the pandemic evolves, healthcare providers treating multiple sclerosis patients must adapt and learn how to quickly develop new protocols to serve patients and their staff in the midst of the broader health crisis. This creates a number of challenges and considerations specifically for healthcare providers in the community setting, including, keeping up to date on care practices in this unique setting where new data and guidance around vaccination is coming out daily.</p> <p>Specifically in the multiple sclerosis space, there is an inconsistent understanding of the vaccine induced antibody and immune response, including T cell antiviral response and how this affects current treatment plans for patients. There is a limited amount of information for healthcare providers to reference how currently authorized SARS-CoV-2 vaccines available in the US work, the factors that impact protective vaccine response in the context of current treatments (ex. DMTs) including pathogen types, vaccine types, medication type mechanism of action, and where medication mechanism of action acts with the vaccine response in order to adjust individual treatment guidance.</p>

<p><b>Support Available:</b> Up to \$250,000</p>	<p>Genentech recognizes the need to support independent education for neurologists and the multiple sclerosis care team to help in keeping up to date in disease management during these unprecedented times. As such, we seek to support independent medical education for neurologists and the multiple sclerosis care team who are managing patients during the COVID-19 pandemic with consideration for newly emerging vaccination data, availability, and guidance.</p> <p><b>References:</b></p> <ol style="list-style-type: none"> <li>1. Louapre C, et al. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. <i>JAMA Neurol.</i> 2020 Sep 1;77(9):1079-1088.</li> <li>2. Multiple Sclerosis &amp; Coronavirus. National Multiple Sclerosis Society.</li> <li>3. COViMS (COVID-19 Infections in MS &amp; Related Diseases). <a href="https://www.covims.org/">https://www.covims.org/</a>.</li> <li>4. Rabi FA, et al. <i>Pathogens.</i> 2020;9(3):231.</li> <li>5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. <i>N Engl J Med.</i> 2020;383(27):2603-2615.</li> <li>6. Callaway E. The race for coronavirus vaccines: a graphical guide. <i>Nature.</i> 2020;580(7805):576-577.</li> <li>7. Abbas AK, Lichtman AH, Pillais, eds. <i>Basic Immunology</i> 6th ed. Elsevier 2019.</li> </ol>
--	--